Chemoablation of metastatic melanoma using intralesional Rose Bengal

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Melanoma research

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CMR.0b013e32831328c7PMID 18830132
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I/II study of topical imiquimod and intralesional interleukin‐2 in the treatment of accessible metastases in malignant melanoma

  2007cited by this paper
• Long-term Results of Hyperthermic, Isolated Limb Perfusion for Melanoma: A Reflection of Tumor Biology

  2007cited by this paper
• Randomized Controlled Study of Electrochemotherapy in the Local Treatment of Skin Metastases of Melanoma

  2006cited by this paper
• Phase 2 trial of Allovectin-7 in advanced metastatic melanoma

  2006cited by this paper
• Allogeneic and Autologous Melanoma Vaccines: Where Have We Been and Where Are We Going?

  2006cited by this paper
• Rose Bengal induces dual modes of cell death in melanoma cells and has clinical activity against melanoma

  2006cited by this paper
• Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy)

  2005cited by this paper
• Cutaneous melanoma.

  2005cited by this paper
• Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

  2003cited by this paper
• Adjuvant therapy for high‐risk primary and resected metastatic melanoma

  2003cited by this paper
• Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma

  2003cited by this paper
• A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma

  2003cited by this paper
• AJCC Cancer Staging Manual. 6th ed

  2002cited by this paper
• Imaging photosensitizer distribution and pharmacology using multiphoton microscopy

  2002cited by this paper
• Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.

  2001cited by this paper
• Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

  2001cited by this paper
• Vaccines for melanoma: translating basic immunology into new therapies.

  2001cited by this paper
• Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7, an HLA-B7/β2-Microglobulin DNA-Liposome Complex, in Patients with Metastatic Melanoma

  2001cited by this paper
• Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

  2001cited by this paper
• Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Phase I trial of interferon-γ (IFN-γ) retroviral vector administered intratumorally to patients with metastatic melanoma

  1999cited by this paper
• Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma.

  1999cited by this paper
• Human gene therapy for melanoma: CT-guided interstitial injection.

  1997cited by this paper
• Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.

  1993cited by this paper
• Cutaneous melanoma.

  1993cited by this paper
• Intralesional interferon‐alpha therapy in advanced malignant melanoma

  1988cited by this paper
• Suitability criteria for compartmental analysis of the plasma clearance curve of exogenous cholephils. 131I Rose Bengal fulfils these criteria.

  1979cited by this paper
• Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion.

  1979cited by this paper
• Investigation of Rose Bengal Conjugation.∗

  1960cited by this paper

• Effect of concentration on singlet oxygen generation from xanthene-based photosensitizers

  2025cites this paper
• Regional Therapies for Melanoma and Merkel Cell Carcinoma.

  2025cites this paper
• A phase 1 study to assess the safety, tolerability and effectiveness of PV-10 (Rose Bengal Sodium) in neuroendocrine tumours metastatic to the liver

  2025cites this paper
• PV-10 enhances immune responses in hepatitis B vaccination through STING pathway

  2025cites this paper
• Improved pharmacokinetic and lymphatic uptake of rose Bengal after transfersome intradermal deposition using hollow microneedles.

  2024cites this paper
• Evaluating the efficacy of Rose Bengal-PVA combinations within PCL/PLA implants for sustained cancer treatment

  2024cites this paper
• Intralesional and Infusional Updates for Metastatic Melanoma

  2024cites this paper
• The evolution of melanomology: a tale of giants' shoulders and bold hypotheses.

  2024cites this paper
• Photodynamic Therapy Using a Rose-Bengal Photosensitizer for Hepatocellular Carcinoma Treatment: Proposition for a Novel Green LED-Based Device for In Vitro Investigation

  2024cites this paper
• Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10

  2024cites this paper
• A new ratiometric fluorescence nanosensor based on NaYF4:3%Er@NaYF4 upconversion nanoparticles for sensitive determination of Rose Bengal in water.

  2023cites this paper
• Fluorescence-Coupled Techniques for Determining Rose Bengal in Dermatological Formulations and Their Application to Ex Vivo Skin Deposition Studies

  2023cites this paper
• Chemo-immunoablation of solid tumors: A new concept in tumor ablation

  2023cites this paper
• Enhanced Delivery of Rose Bengal by Amino Acids Starvation and Exosomes Inhibition in Human Astrocytoma Cells to Potentiate Anticancer Photodynamic Therapy Effects

  2022cites this paper
• Intratumoral therapies and in-situ vaccination for melanoma

  2022cites this paper
• Coimmunomodulation of tumor and tumor-draining lymph nodes during in situ vaccination promotes antitumor immunity

  2022cites this paper
• Anti-PD-1 checkpoint blockade improves the efficacy of a melphalan-based therapy in experimental melanoma.

  2021cites this paper
• Improving Dermal Delivery of Rose Bengal by Deformable Lipid Nanovesicles for Topical Treatment of Melanoma

  2021cites this paper
• Nanotechnology-based rose Bengal: A broad-spectrum biomedical tool

  2021cites this paper
• Treatment of in-transit melanoma metastases using intralesional PV-10

  2021cites this paper
• Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies

  2021cites this paper
• In-transit metastatic cutaneous melanoma: current management and future directions

  2021cites this paper
• Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy

  2021cites this paper
• Current status of intralesional agents in treatment of malignant melanoma

  2021cites this paper
• Immunotherapy for Melanoma.

  2021cites this paper
• Non-Operative Options for Loco-regional Melanoma.

  2021cites this paper
• Local and regional therapy for primary and locally recurrent melanoma.

  2021cites this paper
• A study of Rose Bengal against a 2-keto-3-deoxy-d-manno-octulosonate cytidylyltransferase as an antibiotic candidate

  2020cites this paper
• Local and Recurrent Regional Metastases of Melanoma

  2020cites this paper
• Injectable Therapies for Regional Melanoma.

  2020cites this paper
• Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma

  2020cites this paper
• Management of Locoregionally Advanced Melanoma.

  2020cites this paper
• Intratumoural immunotherapies in oncology.

  2020cites this paper
• Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study

  2020cites this paper
• Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma

  2020cites this paper
• Immunotherapy for Melanoma.

  2020cites this paper
• Identification of a Noncanonical Necrotic Cell Death Triggered via Enhanced Proteolysis by a Novel Sapogenol Derivative.

  2020cites this paper
• Sonodynamic therapy-derived multimodal synergistic cancer therapy.

  2020cites this paper
• ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee

  2020cites this paper
• ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee.

  2020cites this paper
• Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials.

  2020cites this paper
• A systematic review and meta‐analysis of locoregional treatments for in‐transit melanoma

  2019cites this paper
• Development of individualized surgical treatments for malignant melanoma

  2019cites this paper
• Molecular Tools to Generate Reactive Oxygen Species in Biological Systems.

  2019cites this paper
• Intratumoral Immunotherapy—Update 2019

  2019cites this paper
• Isolated Limb Perfusion and Infusion in the Management of In-Transit Melanoma of the Extremities: Modern Data Affecting Practice

  2019cites this paper
• Patients with in‐transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PV‐10—A propensity score matched, single center study

  2019cites this paper
• Intralesional Therapies: Oncolytic Viral Therapies, Immunostimulants

  2019cites this paper
• Rose Bengal The pink eye stain that might be a cancer treatment would you want pink eyes? Is it a fashion?

  2019cites this paper
• Topical and intralesional therapies for in-transitmelanoma

  2019cites this paper
• Local and Recurrent Regional Metastases of Melanoma

  2019cites this paper
• Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma

  2019influential citation
• Novel Immunotherapies and Novel Combinations of Immunotherapy

  2019cites this paper
• Novel Targets for the Treatment of Melanoma

  2019cites this paper
• Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers

  2019cites this paper
• Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma

  2019cites this paper
• Management of Locally and Regionally Recurrent Melanoma

  2018cites this paper
• Intralesional PV‐10 for the treatment of in‐transit melanoma metastases—Results of a prospective, non‐randomized, single center study

  2018influential citation
• T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model

  2018cites this paper
• Regional therapies for locoregionally advanced and unresectable melanoma

  2018cites this paper
• Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience

  2018cites this paper
• Immunotherapy for Melanoma.

  2018cites this paper
• Management of local or regional non‐nodal disease

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Management of Melanoma Locoregional Recurrence

  2018cites this paper
• History of Melanoma

  2018cites this paper
• Treatment of Metastatic Melanoma

  2018cites this paper
• Intralesional therapy as a treatment for locoregionally metastatic melanoma

  2018cites this paper
• Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series

  2017cites this paper
• Intralesional treatment of metastatic melanoma: a review of therapeutic options

  2017cites this paper
• Results of a phase II, open‐label, non‐comparative study of intralesional PV‐10 followed by radiotherapy for the treatment of in‐transit or metastatic melanoma

  2017cites this paper
• Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death

  2017cites this paper
• Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

  2016cites this paper
• Advances in the development of intralesional therapies for melanoma.

  2016cites this paper
• Novel melanoma therapy

  2016cites this paper
• Developments in Intralesional Therapy for Metastatic Melanoma.

  2016cites this paper
• Intralesional PV‐10 for in‐transit melanoma—A single‐center experience

  2016cites this paper
• Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology.

  2016cites this paper
• Intralesional immunotherapy as a strategy to treat melanoma

  2016influential citation
• Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1

  2016cites this paper
• Intralesional therapy for advanced melanoma: promise and limitation

  2015cites this paper
• The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses

  2015cites this paper
• The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options

  2015cites this paper
• Intralesional therapy for in-transit and satellite metastases in melanoma.

  2015cites this paper
• Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

  2015cites this paper
• Radiotherapy for cutaneous melanoma: current and future applications.

  2015cites this paper
• Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis.

  2014cites this paper
• Isolated limb perfusion for in‐transit melanoma metastases: Melphalan or TNF‐melphalan perfusion?

  2014cites this paper
• Isolated limb perfusion with melphalan for melanoma

  2014cites this paper
• Immunomodulation of malignant melanoma by contact sensitizing agents

  2014cites this paper
• A Preclinical Study Combining the DNA Repair Inhibitor Dbait with Radiotherapy for the Treatment of Melanoma

  2014cites this paper
• Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma

  2014cites this paper
• Melanoma vaccines, revisited: a review, update.

  2014cites this paper
• Locoregional therapies in melanoma.

  2014cites this paper
• Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma

  2014cites this paper
• In vitro inhibition of human liver cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes by rose bengal: system-dependent effects on inhibitory potential

  2014cites this paper
• Evolving role of tumor antigens for future melanoma therapies.

  2014cites this paper
• Intralesional therapy with PV‐10 (Rose Bengal) for in‐transit melanoma

  2014cites this paper
• Mitochondrial routing of glucose and sucrose polymers after pinocytotic uptake: avenues for drug delivery.

  2014cites this paper
• Subcutaneous metastases from melanoma: a discussion of clinical experience.

  2014cites this paper